GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on ...

Hims & Hers, the telehealth company, saw its stock price range from under $6 to over $25 during the last 52 weeks. Click here ...

Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x ...

A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

The popularity of the newest weight loss medications has employers reevaluating their health plans. There are a lot of unknowns, but here’s what we do know based on the data.

Karla Robinson, MD and Medical Editor at GoodRx discusses how GLP-1 receptor agonists work and their benefits.

While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face ...

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes ... That’s the day the company will make its case before the FDA’s Gastrointestinal Drugs Advisory ...

Currently, Ozempic remains atop the other GLP-1 drugs on this list, but the drug has been available for longer. As the other drugs on this list become more prominent in the healthcare industry ...